A phase II study of PTK787/ZK 222584 [vatalanib], a novel, oral angiogenesis inhibitor as post transplant maintenance therapy in patients with multiple myeloma following high dose chemotherapy and autologous stem cell transplant

Trial Profile

A phase II study of PTK787/ZK 222584 [vatalanib], a novel, oral angiogenesis inhibitor as post transplant maintenance therapy in patients with multiple myeloma following high dose chemotherapy and autologous stem cell transplant

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2013

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Aug 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 10 Jun 2008 The expected completion date for this trial is now 1 Jun 2009, as reported by ClinicalTrials.gov.
    • 28 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top